The UNC Hemophilia & Thrombosis Center hosts promising young hematologists and fellows who are desirous of the opportunity to further their experience in the diagnosis and management of patients with bleeding and clotting disorders. In the successful tradition of UNC, clinical training is carried out in the context of a research-intensive environment. Training includes exposure to basic science and clinical research as well as comprehensive diagnosis and treatment of affected patients. Many prominent hemophilia physicians in the US and around the world have received training at UNC over the past 30 years. For more information about the program and how to apply, contact Christine Hill, Coagulation Fellowship Coordinator, at firstname.lastname@example.org.
Gautam Kale, MD, MS, is a third-year Hematology/Oncology fellow (Chief Fellow) at the University of Missouri who did a benign hematology rotation at UNC for in September, 2015. He said of his rotation, "To me, this experience was exactly what I was looking for to polish my some of my clinical understanding of this complicated area of hematology where available expertise is limited across the country. I absolutely loved this rotation and would strongly recommend it to any other fellows that may be fortunate enough to have this opportunity."
Ateefa Chaudhury, MD, grew up in Albuquerque, NM and entered the combined Baccalaureate/MD Program at University of Southern California (USC) in Los Angeles, CA after high school. Upon completion of her undergraduate degree, she returned to Albuquerque to spend more time with her family, and she graduated medical school from University of New Mexico in 2011. She finished her Internal Medicine Residency at University of Arizona in 2014. She is currently a second-year fellow at University of South Florida and Moffitt Cancer Center. In residency, her research focused on molecular diagnostics and risk analysis in breast cancer in an underserved population. However, soon after she began her fellowship training she changed her interest from breast cancer to molecular aspects of prognosis and drug targeting in hematologic malignancies. She previously has been selected as a participant in the Hemostasis and Thrombosis Research Society Coagulation Disorders Workshop in 2014 and also attended the Center for Advanced Training in Hemophilia and Inhibitor Management at Tulane University in 2015. This October, she is doing a special elective in benign hematology (primarily hemostasis and thrombosis) at the University of North Carolina, Chapel Hill.